Compugen Reports Second Quarter 2025 Results
Trade with 70% Backtested Accuracy
Analyst Views on CGEN
About CGEN
About the author
Compugen Appoints New Independent Director
- New Board Member: Compugen appointed Dr. Michele Holcomb as an independent director effective February 11, 2026, bringing over 30 years of experience in biotech and pharmaceuticals, which is expected to enhance the board's strategic guidance and innovation capabilities.
- Financial Strength Context: Entering 2026, Compugen is in a position of financial strength with multiple potential first-in-class clinical programs and two validating pharma partnerships, and Holcomb's expertise will help convert these opportunities into long-term value.
- Rich Industry Experience: Previously serving as Chief Strategy Officer at Cardinal Health, Holcomb defined strategies and optimized portfolios, and her extensive experience in various executive roles will provide crucial support for Compugen's innovation and growth.
- Strategic Partnership Potential: Holcomb's deep background in biotechnology and insights into the healthcare industry will assist Compugen in identifying and seizing new growth opportunities in a competitive market, driving the company's continued success.
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
- Financial Strengthening: Compugen's agreement with AstraZeneca to monetize future royalties from rilvegostomig is expected to enhance its financial position, extending its cash runway into 2029 and providing ongoing support for its innovative immuno-oncology pipeline.
- Strategic Collaboration: The amended exclusive license agreement aims to bolster Compugen's capabilities in immuno-oncology, reflecting the significant potential value of rilvegostomig and further solidifying the company's market position in cancer treatment.
- Pipeline Expansion: Rilvegostomig, a PD-1/TIGIT bispecific antibody developed in collaboration with AstraZeneca, is currently in Phase 3 development, highlighting its importance in clinical trials and potential as a key future product.
- Innovative Platform Utilization: Compugen leverages its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets, advancing the development of immunotherapies and showcasing the company's technological advantages and market potential in cancer treatment.
Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal
- Capital Injection: Compugen's agreement with AstraZeneca secures a $65 million upfront payment, with an additional $25 million contingent on the next milestone, significantly enhancing the company's financial position and extending its cash runway into 2029.
- Royalty Retention: By retaining the majority of future royalties, Compugen ensures potential earnings of up to $195 million from rilvegostomig's success, reflecting the company's confidence in the product and providing long-term value for shareholders.
- Pipeline Advancement: This transaction supports the advancement of Compugen's innovative immuno-oncology pipeline, enabling the company to continue developing unique therapeutic solutions while maintaining significant upside from rilvegostomig's potential success.
- Market Outlook: As a first-in-class dual-checkpoint inhibitor undergoing 11 Phase 3 trials, rilvegostomig presents substantial market opportunities for Compugen, further solidifying its leadership position in the cancer immunotherapy sector.
Compugen's Stock Increases Following Royalty Agreement with AstraZeneca
Compugen's Stock Surge: Compugen's shares rose approximately 16% in premarket trading following an agreement with AstraZeneca to monetize future royalties from its cancer drug rilvegostomig.
Agreement Details: AstraZeneca amended a 2018 license deal to acquire part of Compugen's royalty interest, while Compugen retains the majority of future royalties as the drug is in late-stage development for various cancers.
Financial Impact: The deal provides Compugen with $65 million upfront and a potential additional $25 million contingent on FDA marketing application acceptance, extending its cash runway into 2029.
Future Prospects: The non-dilutive financing is expected to support Compugen's ongoing development efforts and financial stability as it advances its cancer treatment initiatives.
Compugen Reports Third Quarter 2025 Results
Clinical Trials Update: Compugen presented Phase 1 data for COM701 at ESMO 2025, showing promising results in platinum-resistant ovarian cancer, and is currently enrolling patients in the MAIA-ovarian platform trial with interim analysis expected in Q1 2027.
Partnership Developments: AstraZeneca shared positive results for rilvegostomig in NSCLC and bladder cancer at ESMO 2025, highlighting the potential of their Fc-reduced anti-TIGIT antibody format, which may improve efficacy and safety.
Financial Position: Compugen reported a cash position of approximately $86.1 million as of September 30, 2025, with expectations to fund operations into Q3 2027, despite a net loss of about $6.98 million for the third quarter.
Pipeline and Future Prospects: The company is advancing its immuno-oncology pipeline, including GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead, and aims to leverage its AI/ML platform for novel cancer therapies.
Compugen Appoints New Independent Director
- New Board Member: Compugen appointed Dr. Michele Holcomb as an independent director effective February 11, 2026, bringing over 30 years of experience in biotech and pharmaceuticals, which is expected to enhance the board's strategic guidance and innovation capabilities.
- Financial Strength Context: Entering 2026, Compugen is in a position of financial strength with multiple potential first-in-class clinical programs and two validating pharma partnerships, and Holcomb's expertise will help convert these opportunities into long-term value.
- Rich Industry Experience: Previously serving as Chief Strategy Officer at Cardinal Health, Holcomb defined strategies and optimized portfolios, and her extensive experience in various executive roles will provide crucial support for Compugen's innovation and growth.
- Strategic Partnership Potential: Holcomb's deep background in biotechnology and insights into the healthcare industry will assist Compugen in identifying and seizing new growth opportunities in a competitive market, driving the company's continued success.
HC Wainwright Initiates Buy on Jade Biosciences with $25 Price Target
- Rating Initiation: HC Wainwright & Co. analyst Arthur He initiated coverage on Jade Biosciences Inc (NASDAQ:JBIO) with a Buy rating and a price target of $25, reflecting confidence in the company's future growth potential.
- Market Performance: Jade Biosciences shares closed at $13.17 on Tuesday, and the analyst's target price implies an upside of over 89%, which could attract more investor interest in the stock.
- Industry Outlook: With the ongoing development in the biotech sector, Jade Biosciences' new products and technologies are expected to drive market share growth, and the positive rating may further enhance market confidence in the company.
- Investor Attention: The analyst's Buy rating and high price target could prompt more institutional investors to consider increasing their positions in the stock, thereby enhancing its liquidity and market recognition.
Compugen Agrees with AstraZeneca to Monetize Future Royalties of Rilvegostomig
- Financial Strengthening: Compugen's agreement with AstraZeneca to monetize future royalties from rilvegostomig is expected to enhance its financial position, extending its cash runway into 2029 and providing ongoing support for its innovative immuno-oncology pipeline.
- Strategic Collaboration: The amended exclusive license agreement aims to bolster Compugen's capabilities in immuno-oncology, reflecting the significant potential value of rilvegostomig and further solidifying the company's market position in cancer treatment.
- Pipeline Expansion: Rilvegostomig, a PD-1/TIGIT bispecific antibody developed in collaboration with AstraZeneca, is currently in Phase 3 development, highlighting its importance in clinical trials and potential as a key future product.
- Innovative Platform Utilization: Compugen leverages its AI/ML-powered computational discovery platform (Unigen™) to identify novel drug targets, advancing the development of immunotherapies and showcasing the company's technological advantages and market potential in cancer treatment.
Compugen Secures $65 Million Upfront Payment in AstraZeneca Deal
- Capital Injection: Compugen's agreement with AstraZeneca secures a $65 million upfront payment, with an additional $25 million contingent on the next milestone, significantly enhancing the company's financial position and extending its cash runway into 2029.
- Royalty Retention: By retaining the majority of future royalties, Compugen ensures potential earnings of up to $195 million from rilvegostomig's success, reflecting the company's confidence in the product and providing long-term value for shareholders.
- Pipeline Advancement: This transaction supports the advancement of Compugen's innovative immuno-oncology pipeline, enabling the company to continue developing unique therapeutic solutions while maintaining significant upside from rilvegostomig's potential success.
- Market Outlook: As a first-in-class dual-checkpoint inhibitor undergoing 11 Phase 3 trials, rilvegostomig presents substantial market opportunities for Compugen, further solidifying its leadership position in the cancer immunotherapy sector.
Compugen's Stock Increases Following Royalty Agreement with AstraZeneca
Compugen's Stock Surge: Compugen's shares rose approximately 16% in premarket trading following an agreement with AstraZeneca to monetize future royalties from its cancer drug rilvegostomig.
Agreement Details: AstraZeneca amended a 2018 license deal to acquire part of Compugen's royalty interest, while Compugen retains the majority of future royalties as the drug is in late-stage development for various cancers.
Financial Impact: The deal provides Compugen with $65 million upfront and a potential additional $25 million contingent on FDA marketing application acceptance, extending its cash runway into 2029.
Future Prospects: The non-dilutive financing is expected to support Compugen's ongoing development efforts and financial stability as it advances its cancer treatment initiatives.
Compugen Reports Third Quarter 2025 Results
Clinical Trials Update: Compugen presented Phase 1 data for COM701 at ESMO 2025, showing promising results in platinum-resistant ovarian cancer, and is currently enrolling patients in the MAIA-ovarian platform trial with interim analysis expected in Q1 2027.
Partnership Developments: AstraZeneca shared positive results for rilvegostomig in NSCLC and bladder cancer at ESMO 2025, highlighting the potential of their Fc-reduced anti-TIGIT antibody format, which may improve efficacy and safety.
Financial Position: Compugen reported a cash position of approximately $86.1 million as of September 30, 2025, with expectations to fund operations into Q3 2027, despite a net loss of about $6.98 million for the third quarter.
Pipeline and Future Prospects: The company is advancing its immuno-oncology pipeline, including GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead, and aims to leverage its AI/ML platform for novel cancer therapies.
